Literature DB >> 620950

Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate.

J Bonte, J M Decoster, P Ide, G Billiet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 620950     DOI： 10.1016/0090-8258(78)90006-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  4 in total

Review 1.  Current impact of adjuvant chemotherapy in resectable cancer.

Authors:  A Rossi; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

Authors:  Amit M Oza; Laurie Elit; Ming-Sound Tsao; Suzanne Kamel-Reid; Jim Biagi; Diane Michele Provencher; Walter H Gotlieb; Paul J Hoskins; Prafull Ghatage; Katia S Tonkin; Helen J Mackay; John Mazurka; Joana Sederias; Percy Ivy; Janet E Dancey; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

3.  Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.

Authors:  V Tamassia; A Battaglia; F Ganzina; A M Isetta; G Sacchetti; F Cavalli; A Goldhirsch; K Brunner; G Bernardo; G Robustelli della Cuna
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Recurrent Endometrial Cancer: Local and Systemic Treatment Options.

Authors:  Heidi Rütten; Cornelia Verhoef; Willem Jan van Weelden; Anke Smits; Joëlle Dhanis; Nelleke Ottevanger; Johanna M A Pijnenborg
Journal:  Cancers (Basel)       Date:  2021-12-14       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.